CLINICAL TRIALS PROFILE FOR SIKLOS
✉ Email this page to a colleague
All Clinical Trials for SIKLOS
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT01976416 ↗ | Novel Use Of Hydroxyurea in an African Region With Malaria | Completed | Children's Hospital Medical Center, Cincinnati | Phase 3 | 2014-09-01 | Multiple studies have shown that hydroxyurea has clinical efficacy in preventing acute painful episodes and reducing the need for blood transfusions in children with sickle cell anemia (SCA), but no study has been conducted in malaria endemic regions of sub-Saharan Africa, the areas with the most children with SCA. The primary goal of this study is to investigate the safety and efficacy of hydroxyurea for children with SCA in a malaria endemic region within sub-Saharan Africa. |
NCT01976416 ↗ | Novel Use Of Hydroxyurea in an African Region With Malaria | Completed | Doris Duke Charitable Foundation | Phase 3 | 2014-09-01 | Multiple studies have shown that hydroxyurea has clinical efficacy in preventing acute painful episodes and reducing the need for blood transfusions in children with sickle cell anemia (SCA), but no study has been conducted in malaria endemic regions of sub-Saharan Africa, the areas with the most children with SCA. The primary goal of this study is to investigate the safety and efficacy of hydroxyurea for children with SCA in a malaria endemic region within sub-Saharan Africa. |
NCT01976416 ↗ | Novel Use Of Hydroxyurea in an African Region With Malaria | Completed | Makerere University | Phase 3 | 2014-09-01 | Multiple studies have shown that hydroxyurea has clinical efficacy in preventing acute painful episodes and reducing the need for blood transfusions in children with sickle cell anemia (SCA), but no study has been conducted in malaria endemic regions of sub-Saharan Africa, the areas with the most children with SCA. The primary goal of this study is to investigate the safety and efficacy of hydroxyurea for children with SCA in a malaria endemic region within sub-Saharan Africa. |
NCT01976416 ↗ | Novel Use Of Hydroxyurea in an African Region With Malaria | Completed | Mulago Hospital, Uganda | Phase 3 | 2014-09-01 | Multiple studies have shown that hydroxyurea has clinical efficacy in preventing acute painful episodes and reducing the need for blood transfusions in children with sickle cell anemia (SCA), but no study has been conducted in malaria endemic regions of sub-Saharan Africa, the areas with the most children with SCA. The primary goal of this study is to investigate the safety and efficacy of hydroxyurea for children with SCA in a malaria endemic region within sub-Saharan Africa. |
NCT01976416 ↗ | Novel Use Of Hydroxyurea in an African Region With Malaria | Completed | Indiana University | Phase 3 | 2014-09-01 | Multiple studies have shown that hydroxyurea has clinical efficacy in preventing acute painful episodes and reducing the need for blood transfusions in children with sickle cell anemia (SCA), but no study has been conducted in malaria endemic regions of sub-Saharan Africa, the areas with the most children with SCA. The primary goal of this study is to investigate the safety and efficacy of hydroxyurea for children with SCA in a malaria endemic region within sub-Saharan Africa. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for SIKLOS
Condition Name
Clinical Trial Locations for SIKLOS
Trials by Country
Clinical Trial Progress for SIKLOS
Clinical Trial Phase
Clinical Trial Sponsors for SIKLOS
Sponsor Name